As an expert preclinical development platform for new anti-infectives, iCAIR® covers the drug development chain from ideas via target identification and hit-to-lead to the non-clinical proof of concept.
- iCAIR® offers e.g. academic groups, spin-offs, and small- and medium-sized enterprises (SMEs) access to high-quality R&D services, expertise and infrastructure to bridge the gap between basic research and regulatory development.
- iCAIR® provides a customized development plan, planning and performance of preclinical studies, and regulatory support in a one-stop-shop concept.
- iCAIR® enables you to develop your early-stage compounds to the stage of preclinical proof of concept, ready to go into regulatory development for market approval or out-licensing to industry partners.